STORM Therapeutics is a University of Cambridge, UK spin-out, translating the ground breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics and RNA modifying enzymes into the discovery of first-in-class drugs in oncology and other diseases.
The discovery of reversible chemical modifications of RNA, their role in changing RNA activity and regulating key processes within the cell gave rise to the concept of RNA epigenetics. There is a growing understanding of the importance of RNA modifications in the development of cancer and other diseases, providing a wealth of novel therapeutic targets for drug discovery.
We work hand in hand with our founders research groups using cutting-edge techniques such as chemical biology, RNA-Seq and RNA mass spectrometry to elucidate the functional role of diverse RNA modifications and identify their protein writers, readers and erasers.
We have established a pipeline of drug discovery programmes to develop novel, first-in-class drugs for the treatment of specific cancers with high unmet medical need.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.